These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25584895)

  • 1. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.
    Wong PP; Demircioglu F; Ghazaly E; Alrawashdeh W; Stratford MR; Scudamore CL; Cereser B; Crnogorac-Jurcevic T; McDonald S; Elia G; Hagemann T; Kocher HM; Hodivala-Dilke KM
    Cancer Cell; 2015 Jan; 27(1):123-37. PubMed ID: 25584895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy.
    Bridges E; Harris AL
    Cancer Cell; 2015 Jan; 27(1):7-9. PubMed ID: 25584889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis: a sudden rush of blood to the tumour.
    Villanueva MT
    Nat Rev Cancer; 2015 Mar; 15(3):135. PubMed ID: 25652345
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice.
    Liu TG; Huang Y; Cui DD; Huang XB; Mao SH; Ji LL; Song HB; Yi C
    BMC Cancer; 2009 Jul; 9():250. PubMed ID: 19624862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer. Breaching the cancer fortress.
    Olson P; Hanahan D
    Science; 2009 Jun; 324(5933):1400-1. PubMed ID: 19520948
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.
    Friess H; Langrehr JM; Oettle H; Raedle J; Niedergethmann M; Dittrich C; Hossfeld DK; Stöger H; Neyns B; Herzog P; Piedbois P; Dobrowolski F; Scheithauer W; Hawkins R; Katz F; Balcke P; Vermorken J; van Belle S; Davidson N; Esteve AA; Castellano D; Kleeff J; Tempia-Caliera AA; Kovar A; Nippgen J
    BMC Cancer; 2006 Dec; 6():285. PubMed ID: 17156477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
    Du B; Wen X; Wang Y; Lin M; Lai J
    Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
    Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
    BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities.
    Hou JM; Liu JY; Yang L; Zhao X; Tian L; Ding ZY; Wen YJ; Niu T; Xiao F; Lou YY; Tan GH; Deng HX; Li J; Yang JL; Mao YQ; Kan B; Wu Y; Li Q; Wei YQ
    Oncology; 2005; 69(1):81-7. PubMed ID: 16088235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
    Raykov Z; Grekova SP; Bour G; Lehn JM; Giese NA; Nicolau C; Aprahamian M
    Int J Cancer; 2014 Jun; 134(11):2572-82. PubMed ID: 24214898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.
    Zhou S; Yang Y; Yang Y; Tao H; Li D; Zhang J; Jiang G; Fang J
    PLoS One; 2013; 8(7):e68589. PubMed ID: 23874680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine.
    Amoh Y; Li L; Tsuji K; Moossa AR; Katsuoka K; Hoffman RM; Bouvet M
    J Surg Res; 2006 May; 132(2):164-9. PubMed ID: 16500746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
    Jia L; Zhang MH; Yuan SZ; Huang WG
    World J Gastroenterol; 2005 Jan; 11(3):447-50. PubMed ID: 15637766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
    Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
    Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report.
    Guais A; Baronzio G; Sanders E; Campion F; Mainini C; Fiorentini G; Montagnani F; Behzadi M; Schwartz L; Abolhassani M
    Invest New Drugs; 2012 Feb; 30(1):200-11. PubMed ID: 20931262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
    Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
    Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
    Blaauboer A; Booy S; van Koetsveld PM; Karels B; Dogan F; van Zwienen S; van Eijck CHJ; Hofland LJ
    BMC Cancer; 2020 Sep; 20(1):913. PubMed ID: 32967656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.